Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @BioWorld
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioWorld
-
Reactants ignite, China syndrome melts down FDA drug-quality meetinghttps://www.bioworld.com/articles/432879-reactants-ignite-china-syndrome-melts-down-fda-drug-quality-meeting …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead investor sentiment remains flat amid continued focus on next stepshttps://www.bioworld.com/articles/432881-gilead-investor-sentiment-remains-flat-amid-continued-focus-on-next-steps …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Pan-Cancer Project looks closer, sees morehttps://www.bioworld.com/articles/432872-pan-cancer-project-looks-closer-sees-more …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Maat Pharma edges toward FMT data readout with $20M series B roundhttps://www.bioworld.com/articles/432869-maat-pharma-edges-toward-fmt-data-readout-with-20m-series-b-round …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Aimmune follows its FDA approval with two new dealshttps://www.bioworld.com/articles/432877-aimmune-follows-its-fda-approval-with-two-new-deals …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congress must do the seemingly impossible – seek bipartisan solutionshttps://www.bioworld.com/articles/432874-congress-must-do-the-seemingly-impossible-seek-bipartisan-solutions …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Not yet a pandemic, 2019-nCoV has echoes of MERS, SARS, fluhttps://www.bioworld.com/articles/432873-not-yet-a-pandemic-2019-ncov-has-echoes-of-mers-sars-flu …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
South Korean biotech Novelty Nobility has attracted ₩10 billion (US$9 million) in series A funding to develop therapeutic antibodies inhibiting the stem cell factor (SCF)/c-KIT pathway.https://www.bioworld.com/articles/432842-novelty-nobility-attracts-9m-in-series-a-funding-for-nn2101-glp-tox-studies …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Now that HHS Secretary Alex Azar (
@SecAzar) has declared a nationwide public health emergency due to the 2019 novel#coronavirus,@HHSGov is saying it may need more $$$ to help it be as proactive and aggressive as possiblehttps://www.bioworld.com/articles/432849-preventing-a-us-outbreak-emergency-declaration-leads-to-hunt-for-more-funding …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Investors in small and midsized biopharma companies were certainly rewarded in 2019, with group members in the BioWorld Drug Developers index on a tear.https://www.bioworld.com/articles/432848-investors-looking-for-repeat-performance-from-drug-developers …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Don't forget:
@BioWorld continues to offer free access to all our#coronavirus news stories here: https://www.bioworld.com/coronavirusHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At this very early point in the emerging
#CoronavirusOutbreak, knowledge about the virus is insufficient to predict what shape that outbreak will ultimately take.https://www.bioworld.com/articles/432852-researchers-cast-wide-net-for-rapid-draw-weapons-in-2019-ncov-fight …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Novelty Nobility attracts $9M in series A funding for NN2101 GLP tox studieshttps://www.bioworld.com/articles/432842-novelty-nobility-attracts-9m-in-series-a-funding-for-nn2101-glp-tox-studies …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Investors looking for repeat performance from drug developershttps://www.bioworld.com/articles/432848-investors-looking-for-repeat-performance-from-drug-developers …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Coronavirus: Chinese researchers claim TCM herbal remedy could ‘inhibit’ 2019-nCoVhttps://www.bioworld.com/articles/432838-coronavirus-chinese-researchers-claim-tcm-herbal-remedy-could-inhibit-2019-ncov …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Preventing a U.S. outbreak: Emergency declaration leads to hunt for more fundinghttps://www.bioworld.com/articles/432849-preventing-a-us-outbreak-emergency-declaration-leads-to-hunt-for-more-funding …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Researchers cast wide net for rapid-draw weapons in 2019-nCoV fighthttps://www.bioworld.com/articles/432852-researchers-cast-wide-net-for-rapid-draw-weapons-in-2019-ncov-fight …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The National Institute of Allergy and Infectious Diseases has stopped a late-stage HIV vaccine study it sponsored after an interim review by the trial's independent data and safety monitoring board found the regimen failed to prevent HIV.https://www.bioworld.com/articles/432818-experimental-hiv-vaccine-combo-proves-ineffective-in-niaid-trial …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@HHSGov has declared a public health emergency in the U.S. over the#coronavirus in part because a government diagnostic for the virus yields inconsistent results, a fact that may spur the life sciences to provide a solution.https://www.bioworld.com/articles/432813-hhs-declares-public-health-emergency-in-part-because-cdc-test-for-coronavirus-unreliable …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biotech investors had every reason to feel bullish heading into the new decade. Unfortunately, those great expectations were quickly erased during J.P. Morgan Healthcare conference week.https://www.bioworld.com/articles/432805-lukewarm-start-to-year-weighs-heavily-on-sectors-performance …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.